SanegeneBio licenses RNAi candidate to Genentech for $200M upfront
SanegeneBio将RNAi候选药物授权给基因泰克，预付款2亿美元

Genentech will pick up an RNAi candidate from SanegeneBio, a China and US biotech fresh off a $110 million Series B.
基因泰克将从SanegeneBio手中引进一款RNAi候选药物；这家中美生物技术公司刚刚完成1.1亿美元的B轮融资。